Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations.

Simple Summary: Mismatch repair (MMR) system deficiency results in increased mutation rates with consequent microsatellite instability (MSI) and susceptibility to carcinogenesis. Clinically, testing MSI status contributes not only to early Lynch syndrome detection, which is associated with an increased risk of various cancers, but also to predicting the biomarkers of response to immune checkpoint inhibitors. In addition, it works prognostically because patients with the MSI phenotype or deficient MMR system (MSI-H or dMMR) characteristics show improved overall survival compared to patients with microsatellite stability or a proficient MMR system (MSS or pMMR). Here, we compare the two methods for MSI testing and outline the pros and cons of both methodologies, as well as examine their sensitivity, complementation, and degree of concordance to clarify to clinicians the ultimate methodology for MSI testing for different cancer types. Both methods are generally known to produce false negative results under certain circumstances, even in technically ideal situations. It is recommended that both methods ought to be established for determining MSI-H and dMMR status, respectively, for all cancer types as a first-line screening test, regarding the substantial agreement of the two methods in the present study. MMR gene germline mutations are considered a major genetic disorder in patients with hereditary nonpolyposis colon cancer (HNPCC) or Lynch syndrome; A total of 15% of sporadic colon carcinomas are MSI-High. MSI has also been observed in other cancers, such as endometrial, gastric, and ovarian cancer. The aim of the current study was to correlate and outline the optimal method between the molecular testing of the instability of microsatellite DNA regions (MSI status) and the loss of protein expression by immunehistochemistry (MMR). A total of 242 paraffin-embedded tissues from gastrointestinal, gynecological, genitourinary, lung, breast, and unknown primary cancer patients were analyzed for the expression of MLH1/MSH2/MSH6/PMS2 by immunohistochemistry, as well as for the molecular analysis of MSI status using PCR-based molecular fragment analysis. A total of 29 MSI-High patients were detected molecularly, while 23 patients were detected by immunohistochemistry, with rates that are comparable according to the literature. Based on the agreement coefficient of the two methods, a substantial agreement emerged (Kappa = 0.675 with standard error = 0.081, p < 0.001). Despite the substantial agreement, both methods ought to be established to determine MSI-H/dMMR status in all cancer types as a first-line screening test. [ABSTRACT FROM AUTHOR]